CAPTRUST Financial Advisors’s scPharmaceuticals SCPH Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-43,746	Closed	-$167K	–	2704
2025 Q2	$167K	Buy	43,746 +3,621	+9%	+$11.2K	﹤0.01%	2335
2025 Q1	$106K	Buy	40,125 +63	+0.2%	+$205	﹤0.01%	2231
2024 Q4	$142K	Buy	40,062 +21,523	+116%	+$82.4K	﹤0.01%	2182
2024 Q3	$84.5K	Buy	18,539 +4,513	+32%	+$21.8K	﹤0.01%	2208
2024 Q2	$61K	Sell	14,026 -27	-0.2%	-$119	﹤0.01%	2137
2024 Q1	$70.5K	Buy	+14,053	New	+$78.7K	﹤0.01%	2071
2023 Q4	–	Sell	-11,500	Closed	-$81.9K	–	2778
2023 Q3	$81.9K	Buy	+11,500	New	+$90.6K	﹤0.01%	2447
2021 Q3	–	Sell	-39	Closed	–	–	4743
2021 Q2	$0	Hold	39	–	–	﹤0.01%	4638
2021 Q1	$0	Buy	+39	New	+$267	﹤0.01%	4457

Other funds holding SCPH

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return

HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

CAPTRUST Financial Advisors's SCPH Position: Q3 2025 in Review

CAPTRUST Financial Advisors sold out of scPharmaceuticals (SCPH) in Q3 2025, closing a stake of 43,746 shares — an estimated $167K sold.

CAPTRUST Financial Advisors first reported a position in SCPH in Q1 2021 and held it in 9 quarters. The position peaked at $167K in Q2 2025. 110 funds tracked by Wall St. Rank hold SCPH as of Q3 2025.

CAPTRUST Financial Advisors reported no remaining scPharmaceuticals position as of Q3 2025 after selling out during the quarter.
CAPTRUST Financial Advisors sold 43,746 scPharmaceuticals shares in Q3 2025, an estimated $167K.
CAPTRUST Financial Advisors first reported a position in scPharmaceuticals in Q1 2021 and held it in 9 quarters.
CAPTRUST Financial Advisors's scPharmaceuticals position peaked at $167K in Q2 2025.
110 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2025.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2025, filed 19 Nov 2025.